Philogen SpA
PHIL
Company Profile
Business description
Philogen SpA is a biotechnology company engaged in the research and development of antibody-based therapeutics for the treatment of cancer and chronic inflammatory diseases. The company's pipeline includes products such as Nidlegy, Fibromun, Darleukin, and Dekavil, targeting oncology and other serious conditions. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
Contact
Piazza La Lizza No. 7
Siena53100
ITAT: +39 57717816
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
214
Stocks News & Analysis
stocks
Margins have bottomed for ASX listed consumer goods company
Impact of tariffs have been priced in.
stocks
SpaceX rally continues, expanding sky-high valuations
SpaceX has risen 50% from its IPO price to become the second-most-expensive stock under Morningstar’s coverage.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,030.20 | 8.40 | 0.09% |
| CAC 40 | 8,421.14 | 46.84 | -0.55% |
| DAX 40 | 24,985.82 | 40.98 | -0.16% |
| Dow JONES (US) | 51,564.70 | 72.15 | 0.14% |
| FTSE 100 | 10,363.27 | 36.43 | -0.35% |
| HKSE | 23,690.86 | 233.95 | -0.98% |
| NASDAQ | 26,517.93 | 496.28 | 1.91% |
| Nikkei 225 | 72,510.16 | 1,260.09 | 1.77% |
| NZX 50 Index | 13,470.74 | 24.89 | -0.18% |
| S&P 500 | 7,500.58 | 80.48 | 1.08% |
| S&P/ASX 200 | 8,815.20 | 13.30 | 0.15% |
| SSE Composite Index | 4,098.01 | 7.53 | 0.18% |